Supplementary Files
Keywords
Non-steroidal anti-inflammatory drugs
Provocation test
How to Cite
Plaudit
Abstract
Background: The Stevens-Johnson syndrome is a serious skin reaction to drugs, and it is potentially life-threatening. Its handling involves the strict restriction of the drug involved, as well as of the drugs that are similar or structurally related.
Case report: A two-year and eight-month old girl with Stevens-Jonson syndrome that was caused by acetaminophen and ibuprofen. Due to the total restriction of non-steroidal anti-inflammatory drugs, and with the purpose of establishing antipyretic alternatives, an oral provocation test was carried out with the usual dose of oral nimesulide, which was negative for both immediate and late reactions. In order to offer a parenteral alternative, a provocation test was carried out with intravenous dipyrone, with in-hospital monitoring for 48 hours in an administration protocol of 10, 30 and 60 %; one dose per hour, for a total of 400 mg. The provocation test was negative for both immediate and late reactions. Oral nimesulide or parenteral dipyrone were prescribed upon requiring analgesic, anti-inflammatory, or antipyretic medication.
Conclusion: At a pediatric age, febrile symptoms are common and controlling them is fundamental; such that if an allergy to non-steroidal anti-inflammatory drugs and acetaminophen is identified in an infant, an affectation on the quality of life will be entailed.
References
Stevens M, Johnson C. A new eruptive fever associated with stomatitis and ophthalmia: Report of two cases in children. Am. J. Dis. Child. 1922;24(6):526-533. DOI: 10.1001/archpedi.1922.04120120077005
White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, et al. SJS/TEN 2017: building multidisciplinary networks to drive science and translation. J Allergy Clin Immunol. Pract. 2018;6(1):38-69. DOI: 10.1016/j.jaip.2017.11.023
Adegbenro-Omotuyi A, Princess O, Precious A, Favour A, Precious E, Olunu E, et al. Stevens-Johnson Syndrome and toxic epidermal necrolysis; extensive review of reports of drug-induced etiologies, and possible therapeutic modalities. Open Access Maced J Med Sci. 2018;6(4):730-738. DOI: 10.3889/oamjms.2018.148
Yang SC, Hu Su, Zhang SZ, Huang JW, Zhang J, Ji C, et al. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in China. J Immunol Res. 2018;2018:4320195. DOI: 10.1155/2018/4320195
Frey N, Jossi J, Bodmer M, Bircher A, Jick SS, Meier CR, et al. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. 2017;137(6):1240-1247. DOI: 10.1016/j.jid.2017.01.031
Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol. 2017;76(5):811-817.e4. DOI: 10.1016/j.jaad.2016.12.024
Rzany B, Mockenhuupt M, Baur S, Schröder W, Stocker U, Mueller J, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990- 1992): structure and results of a population-based registry. J Clin Epidemiol. 1996;49(7):769-773. DOI: 10.1016/0895-4356(96)00035-2
Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600-1607. DOI: 10.1056/NEJM199512143332404
Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Sidoroff A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35-44. DOI: 10.1038/sj.jid.5701033.
Rajan TV. The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation. Trends Immunol. 2003;24(7):376-379. DOI: 10.1016/s1471-4906(03)00142-x
Saeed HN, Chodosh J. Immunologic mediators in Stevens-Johnson syndrome and toxic epidermal necrolysis. Semin Ophthalmol. 2016;31(1-2):85-90. DOI: 10.3109/08820538.2015.1115255
Lerch M, Mainetti C, Beretta-Piccoli BT, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allerg Immunol. 2017;56(1):147-176. DOI: 10.1007/s12016-017-8654-z
Alerhand S, Cassella C, Koyfman A. Stevens-Johnson syndrome and toxic epidermal necrolysis in the pediatric population: a review. Pediatr Emerg Care. 2016;32(7):472-476. DOI: 10.1097/PEC.0000000000000840
Sekula P, Dunant A, Naldi L, Bouwes JN, Halevy S, Kardaun S, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133(5):1197-1204. DOI: 10.1038/jid.2012.510
Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P, Bastuji-Garin S. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149-153. DOI: 10.1046/j.1523-1747.2000.00061.x
Sassolas B, Haddad C, Dunant A, Liss Y, Bork K, Louet L, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60-68. DOI: 10.1038/clpt.2009.252
Wing R, MR Dor, McQuilkin PA. Fever in the pediatric patient. Emerg Med Clin North Am. 2013;31(4):1073-1096. DOI: 10.1016/j.emc.2013.07.006
Chiappini E, Bortone B, Galli L, Martino M. Guidelines for the symptomatic management of fever in children: systematic review of the literature and quality appraisal with AGREE II. BMJ Open. 2017;7(7):e015404. DOI: 10.1136/bmjopen-2016-015404
Phillips EJ, Bigliardi P, Bircher AJ, Broyles A, Chang YS, Chung WH, et al. Controversies in drug allergy: testing for delayed reactions. J Allergy Clin Immunol. 2019;143(1):66-73. DOI: 10.1016/j.jaci.2018.10.030
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2020 Revista Alergia México